Industry & Services >> CEO Interviews >> January 21, 2005
MICHAEL L. CORRADO, MD Chief Executive Officer of Advanced Biologics has
established himself as an infectious disease expert in the
pharmaceutical industry. After spending eight years with Merck and eight
years with Johnson & Johnson, Dr. Corrado partnered with Howard Solomon
to found Advanced Biologics in 1995. He has been intricately involved in
the complete development of numerous infectious disease compounds, from
pre-clinical work through to marketing application submission. Dr.
Corrado has served as Primary Medical Author of six NDAs, five sNDAs,
and several expert reports submitted to European regulatory bodies.
Included in the impressive list of infectious disease compounds he has
worked on are norfloxacin, ofloxacin, levofloxacin, chibroxin, Mefoxin
test kit. Dr. Corrado has numerous publications and presentations to his
credit and is a member of the IDSA - FDA Anti-infective Guidelines
Committee. He is also a reviewer of anti-microbial agents and
chemotherapy for the Archives of Internal Medicine. Profile
Biologics?
Dr. Corrado: Advanced Biologics is a contract research organization. We
came into existence in February of
